{"id":"W2094875652","doi":"10.1160/th13-07-0543","title":"Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome","year":2014,"lang":"en","type":"article","venue":"Thrombosis and Haemostasis","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Takeda Pharmaceuticals North America","keywords":"Medicine; TIMI; Placebo; Acute coronary syndrome; Myocardial infarction; Incidence (geometry); Clinical endpoint; Internal medicine; Thrombolysis; Gastroenterology; Dose; Adverse effect; Surgery; Anesthesia; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002253616,0.002101018,0.003273844,0.0005406144,0.0003927151,0.0009789995,0.0008268223,0.001789935,0.004273844],"category_scores_gemma":[0.001554153,0.0008740525,0.002122694,0.0003631749,0.0009386225,0.0009519863,0.0004255425,0.003137049,0.0008384963],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005094058,"about_ca_system_score_gemma":0.001277233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006120317,"about_ca_topic_score_gemma":0.001105307,"domain_scores_codex":[0.9993007,0.0003838903,0.00003868544,0.00009872788,0.00005497985,0.0001228964],"domain_scores_gemma":[0.9992089,0.0001839902,0.0001391262,0.0000749101,0.00005857989,0.0003345547],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9279625,0.03109545,0.001367804,0.0004764638,0.0007196074,0.0001197136,0.0001330646,0.0006369327,0.01271561,0.0001290786,0.0007882505,0.02385554],"study_design_scores_gemma":[0.7872245,0.2086172,0.002599422,0.00001116835,0.0001843778,0.00004237621,0.00001625223,0.0002591102,0.000534637,0.00007255349,0.0004219766,0.00001643136],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902776,0.00199276,0.0007062034,0.0004294033,0.0002476505,0.00446551,0.0007288396,0.00009016543,0.001061914],"genre_scores_gemma":[0.9836406,0.001798389,0.002444217,0.001290635,0.0005176132,0.006563456,0.001340063,0.00002634065,0.002378775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004273844,"threshold_uncertainty_score":0.01429737,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1054999647114413,"score_gpt":0.3864084300958795,"score_spread":0.2809084653844382,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}